Nepal approves first domestically produced CAR T-cell therapy
Summary
Nepal has approved its first domestically produced CAR T-cell therapy, enabling advanced treatment for aggressive blood cancers within the country.
Key Points
- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use.
- The therapy targets aggressive blood cancers like B-cell Acute Lymphoblastic Leukaemia and Diffuse Large B-Cell Lymphoma.
- The product was developed by a multidisciplinary team at the Centre for Regenerative Medicine Nepal in Kathmandu.
- The approval allows eligible patients to access advanced treatment locally instead of traveling abroad.
